Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MRK
MRK logo

MRK News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MRK News

Novo Nordisk Faces Challenges but Optimistic Outlook Ahead

4h agoFool

U.S. Healthcare Spending Reaches $5.7 Trillion Amid Growth Trends

6h agoFool

Eli Lilly and Intuitive Surgical's Growth Potential

6h agoNASDAQ.COM

iShares Core High Dividend ETF Outperforms S&P 500

15h agoFool

iShares Core High Dividend ETF Surges Over 15% Year-to-Date

15h agoNASDAQ.COM

Market Health Signals: Strong Performance in Healthcare and Agriculture Stocks

1d agoCNBC

SCHD Delivers 227% Return Over 10 Years with Strong Cash Flow Stability

2d agoYahoo Finance

Schwab U.S. Dividend ETF Shows Strong Performance

4d agoNASDAQ.COM

MRK Events

07/01 15:00
Merck Terminates MK-1167 Alzheimer's Study
Merck has terminated a Phase 2 randomized, placebo-controlled study that was intended to evaluate the efficacy and safety of MK-1167 as adjunctive therapy in participants with mild to moderate Alzheimer's disease dementia, according to a post to ClinicalTrials.gov. The study is no longer looking for participants and the termination notes on the page cite a "business reason."
06/30 14:00
AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."
06/30 13:30
Anthropic Launches Claude Science for Scientific Research
Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang report. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

MRK Monitor News

FDA Approves KEYTRUDA and Trodelvy for TNBC Treatment

Jun 25 2026

Merck's CAPVAXIVE Vaccine Approved for Children, Boosting Market Position

Jun 18 2026

Merck Explores COVID Drug for Ebola Amid Outbreak

Jun 04 2026

Merck's KEYTRUDA Combination Therapy Recommended for Bladder Cancer Approval

May 22 2026

Merck Reports Strong Q1 Results Driven by Keytruda Demand

Apr 30 2026

Merck's Late-Stage Trial with Eisai Fails to Meet Goals

Apr 21 2026

Merck's Keytruda Approved in EU; Analyst Upgrades Price Target

Apr 08 2026

Merck's KEYTRUDA and WELIREG Show Positive Phase 3 Results in Kidney Cancer

Mar 05 2026

MRK Earnings Analysis

No Data

No Data

People Also Watch